Patent intelligence · EP
EP 4681704
NEUE FORMULIERUNGEN VON PITOLISANT
NEUE FORMULIERUNGEN VON PITOLISANT
Patent details — EP 4681704
- Jurisdiction
- EP
- Status
- granted
- Grant date
- Jan 21, 2026
- Expiration
- Jan 16, 2046
- Applicant
- BIOPROJET PHARMA [FR]
- CPC classes
- A61K 9/ 20 A I, A61K 9/ 28 A I, A61K 31/ 4453 A I, A61K/314453
Quick answer
EP 4681704 (NEUE FORMULIERUNGEN VON PITOLISANT) is held by BIOPROJET PHARMA [FR]. Status: granted. Granted Jan 21, 2026. Expires Jan 16, 2046 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BIOPROJET PHARMA [FR]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 9/ 20 A I, A61K 9/ 28 A I, A61K 31/ 4453 A I, A61K/314453, A61K/92009, A61K/92846
More from BIOPROJET PHARMA [FR]
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 4681704?
EP 4681704 (NEUE FORMULIERUNGEN VON PITOLISANT) is held by BIOPROJET PHARMA [FR]. Status: granted. Granted Jan 21, 2026. Expires Jan 16, 2046 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns EP 4681704?
BIOPROJET PHARMA [FR] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 3 pharmaceutical patents for this assignee.
When does EP 4681704 expire?
Our index shows an expiration date of Jan 16, 2046 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.